Subjective Cognitive Decline and Biomarkers of Preclinical Alzheimer's Disease

Purpose of ReviewHere, we have provided an overview of previous biomarker studies to support the importance of subjective cognitive decline (SCD) in early identification of at-risk subjects and differentiation between normal and pathological aging, including Alzheimer's disease (AD). We have identified several major areas that would require future research to address current gaps in knowledge and increase the value of SCD in preclinical AD.Recent FindingsSCD in clinically normal individuals has received increasing attention by clinicians and AD researchers. SCD is etiologically heterogeneous. Biomarker studies have and will continue to increase our knowledge of the biological factors contributing to the manifestation and progression of SCD in AD.SummaryFuture research with current and new generations of biomarkers is needed to disentangle the biological basis of SCD, improve the utility of SCD for early AD diagnosis, and understand factors that influence SCD characteristics, including sex differences and cognitive reserve.